

FIFTH WORKSHOP ON DRUG PRICING



SCIENTIFIC BOARD

Pier Luigi Canonico
Armando Genazzani
Claudio Jommi

ROME, MAY 16th | 17th, 2019

Under the auspices of:

Istituto Superiore di Sanità



OBJECTIVE

Realizing a multi stakeholder work table to discuss about issues related to the pricing of drugs, focusing on confidentiality and transparency during the P&R process, approach to integrated technologies and the impact of rare diseases and their management on NHS. Experts of international level will be part of the faculty to generate cross-country comparisons.



SESSION

SESSION I
PRICING OF RARE DISEASES DRUGS

SESSION II
CONFIDENTIALITY OF P&R AGREEMENTS AND NEGOTIATED PRICES

SESSION III
PRICING AND INTEGRATED TECHNOLOGIES



THURSDAY, MAY 16th, 2019

13:45 Registration

14:00 Introduction

Pier Luigi Canonico

Armando Genazzani

Claudio Jommi

14:10 Lecture

2019 AIFA strategy in pricing management

Simona Montilla*



SESSION I

PRICING OF RARE DISEASES DRUGS

Chairperson: Pier Luigi Canonico

14:40 Experience from other EU countries

14:40 The experience of the German NHS

Thomas Mittendorf

15:00 The experience of the French NHS

Mondher Toumi

15:20 The experience of the Spanish NHS

Xavier Badia

15:40 The experience of the Italian NHS

Elena Paola Lanati

16:00 Question time

16:30 Coffee break

THURSDAY, MAY 16th, 2019

16:45 Current issues in Italy and possible solutions

Antonio Addis
Riccardo Palmisano
Patrizia Popoli
Daniela Santarelli

17:45 Question time

18:15 Conclusions

MARKET
ACCESS
AWARD

2019

19:45 Market Access Award prize-giving ceremony & Dinner

Presenter: **Francesca Senette**

Palazzo Santa Chiara
piazza Santa Chiara 14

** Invited speaker*

FRIDAY, MAY 17th, 2019



SESSION II

CONFIDENTIALITY OF P&R AGREEMENTS AND NEGOTIATED PRICES

Chairperson: **Armando Genazzani**

09:00 The role of confidentiality in Italy and other Countries
Claudio Jommi

09:45 Discussion
How to improve the negotiation process?
Enrico Costa
Claudio Jommi
Francesca Patarnello
Massimo Riccaboni

10:45 Question time

11:15 Coffee break



SESSION III

PRICING AND INTEGRATED TECHNOLOGIES

Chairperson: **Claudio Jommi**

11:30 State of the art: the meaning of integrated technologies and how to assess them
Paola Minghetti



FRIDAY, MAY 17th, 2019

- 12:00 Case histories:
- 12:00 Oncology
Nello Martini
 - 12:20 Diabetes
Andrea Laurenzi
 - 12:40 Digital Health Future
Alessandro Fulgheri
- 13:00 Question time
- 13:30 Conclusions

** Invited speaker*

SCIENTIFIC BOARD



PIER LUIGI CANONICO

**PROFESSOR OF PHARMACOLOGY
UNIVERSITA' DEL PIEMONTE ORIENTALE**

Pier Luigi Canonico, MD and Specialist in Endocrinology and Metabolic Diseases, became Full Professor of Pharmacology at the Faculty of Medicine and Surgery at the University of Pavia in 1990; in 1999 he moved as Professor of Pharmacology and Pharmacotherapy at the Faculty of Pharmacy of the Università del Piemonte Orientale University in Novara. He was Chairman of the Department of Chemical, Nutritional, Pharmaceutical and Pharmacological Sciences (DISCAFF) from 2000 to 2008, Vice Dean of the Faculty from 2008 to 2009 and Dean from 2009 to 2011, Member of the Board of Directors of the University (2000-2001); actually he is also Member of the Senato Accademico (since 2002). From 2012 Prof. Canonico is Chairman and Dean of the Department of Pharmaceutical Sciences. He was the CEIMS Director from 2012 to 2013, and CEIMS Member of the Board since 2014.

Professor Canonico is member of several national and international scientific societies: among these, the Italian Society of Pharmacology (Councilor for 10 years and President from 2011 to 2013) and the Italian Society of Neuropsychopharmacology (member of the Council since 2006). Among his extra-academic assignments, Member of the Commissione Unica del Farmaco (CUF) (Commission for Drug Approval and Reimbursement) of the Italian Ministry of Health (2001-2003), Vice-president of the Ethical Committee of the Institute for Neurological Research Casimiro Mondino (2006-2010), Member of the Scientific Group for Innovative Pharmacology (Biological Drugs) of the Presidenza del Consiglio dei Ministri (2008-2010), Member of the Regional Committee for the Organization of the Regional Network for Pain Therapy (Regione Piemonte). He is incoming President of ISPOR Italy Rome Chapter.

Prof. Canonico research includes several areas in the field of neuropsychopharmacology, neuroendocrinology, neurobiology, cancer therapy, pharmacogenetics/genomics and issues concerning biotechnology drugs. He is the author of over 200 publications on international journals.



ARMANDO GENAZZANI

**PROFESSOR OF PHARMACOLOGY
UNIVERSITA' DEL PIEMONTE ORIENTALE**

Armando Genazzani graduated in Medicine and Surgery at the University of Catania. He then spent several years in Oxford, Zurich and Cambridge, working mainly on Ca^{2+} -signalling and signal transduction in health and disease. In Cambridge, he was appointed University Lecturer at the Department of Pharmacology and Official Fellow of Clare Hall.

Since 2003 he is Professor of Pharmacology at the Università del Piemonte Orientale, and was appointed full professor in 2011. His research still focuses on the role of signal transduction in health and disease, including Alzheimer's disease and oncological disorders, as well as on pharmacogenetics. He has authored over 150 publications on international journals.

He has also grown an interest in scientific, regulatory and market access-related issues in the pharmaceutical sector. In this area, along with Professor Canonico and Professor Jommi, he organizes a Master in "Regulatory Affairs and Market Access" at the Department of Pharmaceutical Sciences in Novara, was an expert between 2014-2018 of the WHO "International non-proprietary names (INN) Committee", was a member of the WHO "Essential Medicines List" Committee in 2019 and is a member since 2015 of the "Commissione Tecnico-Scientifica" of the Italian Medicines Agency.

SCIENTIFIC BOARD



CLAUDIO JOMMI

**PROFESSOR OF PRACTICE GOVERNMENT HEALTH
AND NOT FOR PROFIT DIVISION
SDA BOCCONI SCHOOL OF MANAGEMENT**

Claudio Jommi is Professor of Practice at SDA Bocconi School of Management (Government, Health and Not for Profit Division). He is also Member of the Executive Committee, Director of the Health Policy Area and Scientific Coordinator of the Pharmaceutical Observatory at Cergas (Centre for Research on Health and Social Care Management), SDA Bocconi.

He is Director of the Master in International Health Management Economics and Policy (Mihmep), 2019-2020 Edition at SDA Bocconi. He is currently Coordinator of the Specialisation of Pharmaceuticals and Medical Technologies at Mihmep where he also teaches Health Economics and Pharmaceutical Policy and Management. He holds many Executive Courses on Health Technology Assessment and Market Access.

He was Associate Professor of Management at the Department of Pharmaceutical Sciences, University of Novara, where he (i) was member of the University Patent Committee, (ii) taught different undergraduate courses (Management of Pharmacy and Pharmacoeconomics; Intellectual Property Rights and Technology Transfer; Economics and Management of Pharmaceuticals) and (iii) was member of the Scientific Board of the Master in Regulatory Affairs and Market Access.

He has been a visiting professor at Essec Business School, Cergy (Paris), at the Herivan K. Haub School of Business, St Joseph University, Philadelphia (US), at the Andrija School of Public Health, Zagreb and the University of Claude Bernard Lyon 1 (European Market Access University Diploma) (Paris). He was the President of the Italian Health Economics Association (2014-2017).

His research activity is focused on Market Access for Medicines and other Medical Technologies, Pharmaceutical Economics, Policy and Management, Health Technology Assessment and Decision Making in Health Care.

He has had his work published in many international and national journals, including Drug Design Development and Therapy, Frontiers in Pharmacology, European Journal of Health Economics, Health Policy, International Journal of Health Planning and Management, Journal of Medical Marketing, Pharmacoeconomics, PLOS and PLOS Neglected Diseases, Public Money and Management, Social Science and Medicine, Value in Health.

He is also the Editor in Chief of the Journal Global and Regional Health Technology Assessment.

He is Member of ISPOR (International Society for Pharmacoeconomics and Outcome Research); he was member of the National Committee by the Consiglio Superiore di Sanità "Economic impact of NIPT – Non-invasive prenatal test – in the Italian National Health Service" and he was Advisor of Aifa (Italian Medicines Agency) to reform the medicines price and reimbursement process. He is also Member of the Scientific Board of the Bioindustry Park, Canavese, Italy.

He systematically participate in international Conferences, such as ISPOR, iHEA (International Health Economics Association) and EUHEA (European Health Economics Association).

He joined international Advisory Boards supporting the Pharmaceutical Companies on Economic Evidence for Market Access purposes.

FACULTY



ANTONIO ADDIS

DEPARTMENT OF EPIDEMIOLOGY, REGIONAL HEALTH SERVICE, REGIONE LAZIO

PhD in pharmacological research (Istituto "Mario Negri" Milano, Italy) and research experience at international (Division of Clinical Pharmacology, Hospital for Sick Children; University of Toronto, Canada 1995-1997) and national (Centre for the Evaluation of Effectiveness and Health Care – CeVEAS, Modena) level. Head of the Office for Drug Information at Ministry of Health, and then of the Italian Medicine Agency-AIFA (2002-2009); National Expert at the European Medicine Agency-EMA in London (2009-2011). Coordinator for the Governance of Research at the Regional Social and Health Agency of Emilia Romagna Region (2012-2015); Delegate for the Ministry of Health and Italian Medicine Agency at the Committee for Medicinal Products for Human Use (CHMP), the World Health Organization (WHO). Principal Investigator for Project supported by European Commission. Currently working as researcher for the Department of Epidemiology of Lazio Region. Member of the Regional Medicine Committee (CoReFa) of Lazio Region. Member of the Ethical Committee of paediatric Hospital Bambino Gesù. Since 2012 Member of the Scientific Committee (CTS) of the Italian Medicine Agency.



XAVIER BADIA

PARTNER & CEO AT OMAKASE CONSULTING, BARCELONA

Xavier Badia is Doctor in Medicine and Master in Health Economics and Public Health by the Autonomous University of Barcelona. Worked in the public sector in different management position within the Catalan Health Service and later dedicated to research and consultancy in HEOR and Pricing and Market Access (PMA) of pharmaceuticals and medical devices in Europe and specifically in the Spanish health care system. Currently Co Founder of Omakase Consulting, focus on Spanish PMA of new drugs and new methodologies such as Multicriteria Decision Analysis (MCDA) and Real World Evidence for Outcomes based innovative agreements between Pharmaceuticals and Payers. Dr Badia experience is mainly in oncology and rare diseases where he help start up companies as well as established Pharmaceutical companies to prepare and entry to the Spanish market. Recently developed a rare disease MCDA to assess value of orphan drug therapy.

Dr. Badia is advisor of the Rare Disease data base of Instituto Carlos III, member of rare disease research network CIBERER, co-owner of a PMA database with all drugs currently approved in the Spanish market since 2012, collaborator of FEDER (Spanish rare disease Patient Federation) and associate professor at Pharmacy faculty at University of Barcelona and responsible of PMA module of postgraduate Master of Scientific Departments of Pharmaceutical industry. He has published more than 200 articles and wrote 3 books and several book chapters. Dr Badia was chairing the European annual meetings of ISPOR held in Barcelona (2003) and Madrid (2011).

FACULTY



ENRICO COSTA

CLINICAL PHARMACIST

Graduated in Pharmacy (University of Bologna) and Specialized in Hospital Pharmacy (University of Milan), since 2004 he has worked at the Department of Pharmacy of the University Hospital of Verona.

Currently a PhD Fellow at the Collaborating Centre for Pharmaceutical Policy and Regulation of the World Health Organization of Utrecht University, the Netherlands.

His scientific interests are focused on improving the affordability and accessibility of drugs, their rational use, strengthening clinical governance practice and global health.

He is also a member of the Ethical Committee of the Veneto Cancer Institute (Istituto Oncologico Veneto) and since 2016 he has been collaborating with the Department of Haematology and the School of Pharmacy of the Muhimbili University of Health and Allied Sciences of Dar es Salaam, Tanzania, on developing projects for the treatment of Sickle Cell Disease.



ALESSANDRO FULGHERI

STRATEGY DIRECTOR, HEALTHWARE INTERNATIONAL

Graduated with honours in Biology, Alessandro started his professional career working for RAI (Italian public broadcasting company) as Author and Director of programs.

Then he worked for about 20 years in several multinational pharmaceutical companies, dealing with product and corporate communication and covering roles of increasing responsibility at national and international level.

From 2006 in Publicis Healthcare, where as Strategic Planning Director operated between the agency offices in Milan, Paris and New York.

Since 2015 he is Strategy Director in Healthware International, the next-gen healthcare marketing agency.

FACULTY



ELENA PAOLA LANATI

MANAGING DIRECTOR, MA PROVIDER, MILAN

Paola has worked for years as a manager in pharmaceutical companies (AstraZeneca, BMS, UCB, P&G), occupying the position of Business Unit Director, first in Primary Care and then in Specialty Care. In her carrier, she managed issues of market access (IPP, oncology, CNS) and dossiers of price negotiation. In 2010 she founded first 3P Solution and then MA Provider for which she won a selection in Lombardia Region for the launch of new companies, thanks to a project on the pricing of new drugs. Businesswoman and Mom, Paola runs a growing team of 30 people, is passionate about pricing and patient advocacy, and loves to make her own contribution and to stimulate the challenges of our healthcare system. Founder and former secretary of Ispor Italy Rome Chapter.



ANDREA LAURENZI

**ADJUNCT PROFESSOR OF ENDOCRINOLOGY
UNIVERSITY VITA-SALUTE SAN RAFFAELE
SID MEMBER OF THE TECHNOLOGY AND DIABETES GROUP**

Andrea Laurenzi graduated in Medicine and Surgery and he specialized in Endocrinology and Metabolic Diseases at University Vita-Salute San Raffaele.

He is coordinator of "Diabetes Area" in Day Hospital of Internal Medicine of San Raffaele Hospital since 2010. The main activities involving this role that he covers are management of patients with type 1/2 diabetes and diabetes complications, investigation in several clinical research trials in diabetes and treatment of gestational and pre-gestational diabetes.

He has been adjunct professor at School of Endocrinology and at Medicine school's Endocrinology Course of Vita-Salute San Raffaele University since 2015.

Moreover, he has been sub-investigator in Type 1 Diabetes TrialNet Study Group since 2011 and he was co-Investigator in several spontaneous and sponsored clinical trials in diabetological field. His research dealing with relatives at risk of type 1 diabetes mellitus, with a special focus on oral insulin's effects and prevention in these subjects.

FACULTY



NELLO MARTINI

PRESIDENT, FONDAZIONE RICERCA E SALUTE, ROMA

Nello Martini graduated in Pharmacy and specialized in Clinical Pharmacology.

From 1973 to April 1998 he directed the pharmacy of the Policlinico Borgo-Rome in Verona.

From May 1998 to June 2004 he was General Director of Drugs and Medical Devices of the Ministry of Health.

Later he held the position of General Director of the Italian Drugs Agency (AIFA) until June 2008, and was a member of the Board of Directors of the EMA.

Previously he held the position of Director of Drugs & Health - Roma

Currently he holds the position of President of Fondazione Ricerca e Salute (ReS) - Roma

He carried out training courses in France and in the United States and is author of over 150 publications including books and scientific articles.



PAOLA MINGHETTI

**PROFESSOR OF PHARMACEUTICAL TECHNOLOGY AND LEGISLATION
UNIVERSITÀ DEGLI STUDI DI MILANO**

Paola Minghetti, graduate in Pharmacy and Industrial Pharmacy, PhD in Pharmaceutical Sciences, is full professor of Pharmaceutical Technology and Legislation at Università degli Studi di Milano.

She is an expert of the Italian Pharmacopoeia and member of a team appointed by EDQM for the creation of the monograph "Pharmaceutical Dosage Forms". She is member of the AIFA evaluation and authorization Secretariat since 2012. The research is mainly related to transdermal and buccal drug delivery systems. to the doctrinal elaboration regards the national and UE legislation related to the production and the commercialization of medicaments, medical devices, and health products.

FACULTY



THOMAS MITTENDORF

MANAGING DIRECTOR, VICE PRESIDENT AT XCENDA GMBH

Thomas Mittendorf, MSc, PhD is a health economist by training and Vice President and Managing Director of Xcenda leading a team of 50 researchers specialized in HTA market access, real world evidence, and health economics.

He is a former Assistant (and later Adjunct) Professor teaching health economics and health system research at the Center for Health Economics at the Leibniz University of Hannover, Germany. His particular interests in recent years have been on health policy and regulatory issues in Germany and Europe as well as health economic research in different diseases and technologies, including oncology, immunology, rare diseases, and orphan drugs. Dr. Mittendorf has a track record of over 120 publications in all related fields of health-related research. Dr. Mittendorf is a former Editor-in-Chief of ISPOR CONNECTIONS and a member of other editorial boards as well as a regular reviewer for multiple journals.



SIMONA MONTILLA

**PHARMACEUTICAL POLICY EXPERT AND HTA ASSESSOR
ITALIAN MEDICINES AGENCY (AIFA)**

Simona Montilla obtained his Chemistry and Pharmaceutical Technologies Degree and a Doctorate Degree in Pharmacology from the University of Rome "La Sapienza".

She is been working as pharmaceutical policies expert since 2005 in Italian Medicines Agency (AIFA).


She has expertise in the regulatory science and analysis of pharmaceutical systems, with a focus on HTA, pricing and reimbursement, pharmacoepidemiology and rational use of medicines, generics and biosimilars, evaluation of pharmaceutical innovation.

She participated to various projects at national and at EU level (including PPRI, EUPHA and EUnetHTA). She has been (co-)author of more than 20 published studies and institutional reports.

Simona Montilla obtained his Chemistry and Pharmaceutical Technologies Degree and a Doctorate Degree in Pharmacology from the University of Rome "La Sapienza". She is been working as pharmaceutical policies expert since 2005 in Italian Medicines Agency (AIFA).

She has expertise in the regulatory science and analysis of pharmaceutical systems, with a focus on HTA, pricing and reimbursement, pharmacoepidemiology and rational use of medicines, generics and biosimilars, evaluation of pharmaceutical innovation. She participated to various projects at national and at EU level (including PPRI, EUPHA and EUnetHTA). She has been (co-)author of more than 20 published studies and institutional reports.

FACULTY



RICCARDO PALMISANO

PRESIDENT OF ASSOBIOTEC-FEDERCHIMICA AND CEO OF MOLMED, MILAN

Riccardo Palmisano, CEO at MolMed, the most relevant Italian Cell&Gene company, listed on the Milan Stock Exchange, is graduated in Medicine at Parma University. His career in the Italian pharmaceutical industry started in 1986 at Farmitalia Carlo Erba (1986). In 1988, he moved on to Menarini Group where contributed to the development and internationalisation of the first Italian pharmaceutical Group, becoming Director of the Pharmaceutical Division Italy (1993) and General Manager at Lusofarmaco (1995). His career in multinational companies started in 2000: he set up the Italian branch of Shire Pharmaceutical (2000), then was appointed Vice President Commercial Retail Market in GlaxoSmithKline Verona (2003) and, lastly, Vice President & General Manager Italy at Genzyme (2005), a U.S. biotech company specialized in research and development of orphan drugs for rare diseases. After the acquisition of Genzyme by Sanofi he was appointed Director of Business Strategy and Development at Sanofi Italia too (2012-2013). Between 2014 and 2015, before moving to MolMed at the end of 2015, Palmisano was Genzyme Italy not operating Chairman of the Board, President of Siena Biotech, as well as member of the Steering Committee of Rare Partners and consultant for some innovative life sciences start-up companies. In 2008, he joined Assobiotech, becoming Vice President, responsible for biotech pharma and health, in 2010. In 2016, he was appointed President of Assobiotech. He is vice president of the Lombardy Life Science Cluster of Assolombarda too.



FRANCESCA PATARNELLO

**VICE PRESIDENT MARKET ACCESS & GOVERNMENT AFFAIRS
ASTRAZENECA ITALIA**

Francesca Patarnello is, since March 2017, Vice President Market Access & Government Affairs, AstraZeneca Italia. Degree in Statistics and Economics, began his career in Farmitalia Carlo Erba, passing successively from Fidia to GlaxoSmithKline. Before AstraZeneca she spent three years as Value and Access Director in Amgen, working to make accessible to patients the innovative pipeline. Before moving to the Market Access, she plays a number of roles in medical science, including HTA Director and Scientific Director and Quality. Member of several working groups, Francesca currently sits on the Board of Directors of SIHTA (Society of Health Technology Assessment) and also held a series of academics positions at the University of Bologna, Catania, Novara, Padova and Verona. She is co-author of numerous publications regarding innovation of drugs, on HTA and on market access.

FACULTY



PATRIZIA POPOLI

**HEAD, NATIONAL CENTER FOR DRUG RESEARCH AND EVALUATION
ISTITUTO SUPERIORE DI SANITÀ, ROMA**

Patrizia Popoli obtained a degree in Medicine and Surgery at the Università degli Studi in Perugia. She majored in neurological clinic at the Università degli Studi in Perugia. Currently, she is the Director of the National Center for Drug Research and Evaluation at Istituto Superiore di Sanità, and member of the Committee for the evaluation of admission to Phase I clinical trials (ISS), of the Ethic Committee of ISS and of the Coordinating Center of Ethic Committees (Italian Drug Agency, AIFA).

She has been for many years permanent substitute of the President of Istituto Superiore di Sanità in the Scientific and Technical Committee of AIFA and is currently President of this Committee.

In the field of experimental research, her activity has been focused on Central Nervous System Pharmacology.

She is a member of scientific societies and author of several publications. Furthermore, she performs numerous regulatory activities in the pharmaceutical sector.



MASSIMO RICCABONI

PROFESSOR OF ECONOMICS, IMT SCHOOL, LUCCA

Massimo Riccaboni is Full Professor of Economics at IMT School for Advanced Studies Lucca. He is the Director of AXES research unit and the head of the PhD track in Economics Networks and Business Analytics at IMT Lucca. He is visiting professor at the Dept. of Managerial Economics, Strategy and Innovation at K.U.Leuven.

He has published, among the others, in Science, PNAS, Nature Reviews, Journal of the European Economic Association, Management Science, Research Policy, Economic Letters, International Journal of Industrial Organization, R&D Management, Health Affairs, Marketing Letters, Health Policy, Small Business Economics, Scientometrics, Physical Review E, New Journal of Physics, Journal of Economic Dynamics and Control, World Economics, Nature Scientific Data, Nature Scientific Reports.

He is an author of the EU reports on "Innovation and Industrial Leadership: Lessons from Pharmaceuticals", "Innovation and Competitiveness in European Biotechnology" and on "Medical Devices Competitiveness and Impact on Public Health Expenditure".

He has been a member of the AIFA's Committee for Prices and Reimbursement (CPR) from 2015 until 2018.

FACULTY



DANIELA SANTARELLI

MARKET ACCESS DIRECTOR ALEXION ITALY

Graduated magna with laude at the University of Pisa in Chemical and Pharmaceutical technologies and with a post doc degree in Regulatory Affairs, she has spent her entire career in the pharmaceutical industry working in the Biotech industry for 3 US-based corporations (Amgen, Intermune and currently Alexion), as well as for European companies (Ipsen and Lundbeck). Since joining Alexion, a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery and development of life-changing therapies, she has focused on developing the Institutional image of Alexion as well as bringing its novel therapies to patients in need as fast as possible. Daniela is a member of various Italian Scientific Societies.



MONDHER TOUMI

**CEO, CREATIV-CEUTICAL
PROFESSOR OF PUBLIC HEALTH, UNIVERSITY OF AIX-MARSEILLE**

Professor Mondher Toumi is M.D. by training, M.Sc. in Biostatistics, and in Biological Sciences (option pharmacology) and Ph.D. in Economic Sciences. Mondher Toumi is Professor of Public Health at Aix-Marseille University. After working for 12 years as Research Manager in the department of pharmacology at the University of Marseille, he joined the Public Health Department in 1993. In 1995 he embraces a career in the pharmaceutical industry for 13 years. Mondher Toumi was appointed Global Vice President at Lundbeck A/S in charge of health economics, outcome research, pricing, market access, epidemiology, risk management, governmental affairs and competitive intelligence. In 2008, he founded Creativ-Ceutical, an international consulting firm dedicated to support health industries and authorities in strategic decision-making. In February 2009 he was appointed Professor at Lyon I University in the Department of Decision Sciences and Health Policies. The same year, he was appointed Director of the Chair of Public Health and Market Access. He launched the first European University Diploma of Market Access (EMAUD) an international course already followed by about 500 students. Additionally, he recently created the Market Access Society to promote research and scientific activities around market access, public health and health economic assessment. Since 2009, he also chairs the Annual Market Access Day, a purely academic event. He is editor in Chief of the Journal of Market Access and Health Policy (JMAHP). Since September 2014, he joined the research unit EA3279 of the public health department, at Aix-Marseille University (France) as full Professor. Mondher Toumi is also visiting Professor at Beijing University (Third Hospital). He is a recognized expert in health economics and an authority on market access and risk management. He has more than 200 scientific publications and oral communications, and has contributed to several books. He authored a reference book on Market Access.

MA AWARD



MARKET ACCESS AWARD 2019

The Market Access Award 2019, at its fifth edition, wants to reward the best partnership between private companies and public institutions aimed to optimize the patient care access through innovative solutions.

The evaluation criteria to assign the prize will be:

- ✓ scientific value of the project
- ✓ benefit to patients
- ✓ innovation and added value in the interaction between private and public
- ✓ replicability of the project

The judging board will be composed by:

Mattia Altini

Direttore Sanitario, Istituto Scientifico Romagnolo per lo studio e per la Cura dei Tumori IRCCS

Pier Luigi Canonico

Direttore del Dipartimento di Scienze del Farmaco, Università degli Studi del Piemonte Orientale

Ivan Gardini

Presidente Epac Onlus

Antonio Gaudio

Segretario Generale di CittadinanzAttiva

Claudio Jommi


Professor of Practice Government, Health and Not for profit Division SDA Bocconi School of Management

Elena Paola Lanati

Managing Director di MA Provider

Manuela Vaccarotto

Vicepresidente AISMME Onlus



ROME, MAY 16th | 17th, 2019



via Vincenzo Monti 3
20123 Milano
tel +39 02 89096682
fax +39 02 89098927
e-mail | info@maprovider.com

piazza San Salvatore in Lauro 10
00186 Roma
tel | fax +39 06 68806614
e-mail | info.roma@maprovider.com

web | www.maprovider.com

